机构：美国政府施压令葛兰素史克盈利前景蒙阴

Core Viewpoint - GlaxoSmithKline faces new uncertainties after agreeing to lower drug prices for American patients, influenced by pressure from the Trump administration [1] Group 1: Company Actions - The company has committed to launching a direct-to-consumer drug procurement platform and strengthening its drug supply chain in the U.S. [1] - These measures are aimed at mitigating potential tariff impacts [1] Group 2: Financial Implications - GlaxoSmithKline has previously pledged significant capital expenditures in the U.S. to reduce trade risks [1] - It remains unclear how these actions will affect the company's profitability [1] Group 3: Market Focus - There is uncertainty regarding whether the company's commitments and investments in the U.S. market have surpassed its focus on the domestic UK market [1]